文献速递前列腺癌

美国Medicare人群中转移性去势抵抗性前列腺癌(mCRPC)男性的真实世界治疗模式与总生存

Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-10-02

基于美国Medicare按服务收费索赔数据,2014年1月1日至2019年6月30日新诊断的14,780例mCRPC男性中,22%未接受任何延长生存治疗,78%接受≥1线治疗,42%接受≥2线,20%接受≥3线。从mCRPC诊断起中位生存为25.6个月,从一线治疗开始起为23.4个月。

要点

  • 在14,780例mCRPC男性中,22%未接受任何延长生存治疗,42%接受≥2线治疗。
  • 最常见的1L至2L序贯为NHT后换用另一种NHT(33%),化疗后NHT(14%),NHT后化疗(13%)。
  • 以NHT为1L者中仅28%后续接受不同类别治疗;mCRPC诊断后中位生存25.6个月。

核心结论

  • 超过五分之一的Medicare mCRPC患者未接受任何延长生存治疗,不足一半接受2L治疗。
  • NHT是最常见的1L和2L治疗,以NHT为1L后换用不同NHT为2L是最常见序贯。
  • 所有患者从诊断起中位生存为25.6个月;数据凸显mCRPC患者尤其NHT以外治疗的明显治疗不足及真实世界中序贯NHT的常见使用。

研究设计与样本

  • 在2014年1月1日至2019年6月30日期间通过Medicare按服务收费索赔数据识别新诊断mCRPC男性。
  • 纳入者需有mCRPC证据且诊断前连续保险覆盖≥1年、诊断后≥6个月,除非患者死亡。
  • 描述诊断后治疗模式,并采用Kaplan-Meier分析从mCRPC诊断起及从一线治疗开始起的生存。

主要发现

  • 共14,780例mCRPC男性,平均年龄76岁,mCRPC后中位随访17.0个月。
  • 22%在mCRPC后未接受延长生存治疗,78%接受≥1线治疗,42%接受≥2线,20%接受≥3线。
  • 从1L开始至下一LOT或随访结束的中位时间为13.7个月,从2L开始为10.9个月,从3L开始为8.9个月。
  • 在≥2线的男性中,最常见1L至2L序贯为NHT后换用另一种NHT(33%)、化疗后NHT(14%)、NHT后化疗(13%)。
  • 以NHT起始1L者中仅28%后续接受不同类别治疗;mCRPC后中位生存25.6个月,治疗开始后中位生存23.4个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world treatment patterns and survival in metastatic castration-resistant prostate cancer (mCRPC) have not been characterized for the full fee-for-service Medicare population. METHODS: Men newly diagnosed with mCRPC were identified in Medicare fee-for-service claims during 1/1/2014-6/30/2019. Men had evidence of mCRPC and continuous insurance coverage ≥1 year before and ≥6 months after diagnosis unless patients died. Treatment patterns after diagnosis were described. Survival from mCRPC diagnosis and from start of first-line (1 L) therapy was modeled using Kaplan-Meier analysis. RESULTS: Among 14,780 men with mCRPC, mean age was 76 and median follow-up after mCRPC was 17.0 months. 22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs. Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start. The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%). For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy. Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation. CONCLUSIONS: More than 1 in 5 Medicare patients with mCRPC did not receive any life-prolonging therapy, and less than half received 2 L therapy. NHTs were the most common 1 L and 2 L therapies, with patients treated with NHT as 1 L followed by a different NHT for 2 L as the most common treatment sequence. Median survival from diagnosis for all patients was 25.6 months. These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Freedland SJ, Davis M, Epstein AJ, et al. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2023. PMID: 37783836. doi:10.1038/s41391-023-00725-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。